Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
To arise and progress, cancers need to evade immune elimination. Consequently, progressing tumors are often MHC class I (MHC-I) low and express immune inhibitory molecules, such as PD-L1, which allows them to avoid the main antitumor host defense, CD8+ T cells. The molecular mechanisms that led to these alterations were incompletely understood. In this study, we identify loss of the transcription factor IRF2 as a frequent underlying mechanism that leads to a tumor immune evasion phenotype in both humans and mice. We identified IRF2 in a CRISPR-based forward genetic screen for genes that controlled MHC-I Ag presentation in HeLa cells. We then found that many primary human cancers, including lung, colon, breast, prostate, and others, frequently downregulated IRF2. Although IRF2 is generally known as a transcriptional repressor, we found that it was a transcriptional activator of many key components of the MHC-I pathway, including immunoproteasomes, TAP, and ERAP1, whose transcriptional control was previously poorly understood. Upon loss of IRF2, cytosol-to–endoplasmic reticulum peptide transport and N-terminal peptide trimming become rate limiting for Ag presentation. In addition, we found that IRF2 is a repressor of PD-L1. Thus, by downregulating a single nonessential gene, tumors become harder to see (reduced Ag presentation), more inhibitory (increased checkpoint inhibitor), and less susceptible to being killed by CD8+ T cells. Importantly, we found that the loss of Ag presentation caused by IRF2 downregulation could be reversed by IFN-stimulated induction of the transcription factor IRF1. The implication of these findings for tumor progression and immunotherapy are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Irf2 was a transcriptional activator of many key components of the major histocompatibility complex class I antigen presentation. 21”
From Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis. (2020) · cites this paper as [21]
In the citing paper
“A positive correlation between IRF2 expression and MHC I has been observed in many human tumors, including CRC [212].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“32 (20) was used to remove 59 or 39 stretches of bases having an average quality of ,20 in a window size of 10.”
MethodPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231 · cited 1×
“0) (23, 24) with default parameters and a model that specified different replicates as batches.”
BackgroundDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Cited by
Items 101–118 of 118
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606790
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606769
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606793
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606781
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606778
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606772
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606787
Cuttano, R., Colangelo, T., Guarize, J., Dama, E., Cocomazzi, M. P., Mazzarelli, F., Melocchi, V., Palumbo, O., Marino, E., Belloni, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606796
Recuperar a imunidade antitumoral com estratégias de reprogramação direta para células dendríticas
Ferreira, A. G. B. (2023) · Lund University Publications (Lund University)
Gallagher, M. P., Conley, J. M., Vangala, P., Reboldi, A., Garber, M. G., & Berg, L. J. (2020) · The Journal of the American Medical Association (JAMA) Network (American Medical Association)
Self-citationIRF2 deficiency disrupts pyroptosis, NK cell interferon-γ production and resistance to Francisella
Cornut, M., Djebali, S., Rondeau, E., Dayet, S., Fayolle, T., Haagen, J., Fallone, L., Rousseaux, N., Caspar, E., Marcotte, M., et al. (2026) · EMBO Reports · doi:10.1038/s44319-026-00698-4
Dissecting KRAS Functional Heterogeneity in Patient-Derived Lung Adenocarcinoma Models
Rosen, J. C. (2025) · TSpace (University of Toronto)
TGFβ-SMAD2/3 signaling inhibits IRF2 to drive metastasis in KRAS-mutant colorectal cancer
Shu, F., Zhang, T., Chen, X., Lu, G., Guo, S., Zhang, Y., Huang, C., Liao, W., & Wang, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218507
Zhao, C., Song, J., Luo, X., Chen, Y., & Jin, F. (2026) · iScience · doi:10.1016/j.isci.2026.116908
Kammerer, S., Bode, P. K., Schreiber, H., & Sánchez, G. O. (2026) · Pathology & Oncology Research · doi:10.3389/pore.2026.1612537
Liang, Y., Ning, Y., Li, X., Feng, P., Liu, Y., & Huang, Y. (2026) · Genes & Genomics · doi:10.1007/s13258-026-01800-9
Yamashita, S., Shuto, H., Hirayama, A., Shimauchi, A., Utsumi, T., Ninomiya, T., Tsubouchi, K., Otsubo, K., Shibahara, D., Iwama, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.23.761340
Sauerer, T., Lischer, C., Weich, A., Berking, C., Vera, J., & Dörrie, J. (2021) · doi:10.3389/fmicb.2021.785662.s002
Metadata
- Authors
- Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Rock, Kenneth L
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-01
- Volume
- 203
- Issue
- 7
- Pages
- 1999-2010
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC6761035
- OpenAlex
- W2970242544
- Cited by
- 114
- References
- 64
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 17 · 2023: 23 · 2022: 18 · 2021: 19 · 2020: 10 · 2019: 2
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM107000)
- National Institute of Allergy and Infectious Diseases (R01AI145932, R01AI114495, T32AI095213)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- IRF2, tumor immune evasion, MHC class I antigen presentation, PD-L1, immunoproteasome, TAP, ERAP1, CD8+ T cells, IRF1, interferon-stimulated genes, transcriptional repressor, cancer immunotherapy
- MeSH terms
- HeLa Cells, Humans, Neoplasm Proteins, Neoplasms, Histocompatibility Antigens Class I, Down-Regulation, Gene Expression Regulation, Neoplastic, Antigen Presentation, CD8-Positive T-Lymphocytes, Tumor Escape, Interferon Regulatory Factor-2, HEK293 Cells, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.